Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers
Contact
  • About
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • News
    • Press Releases
  • Careers

Presentations

SITC Safety and Efficacy

PresentationBy Sensei TeamDecember 12, 2020

Early Safety and Efficacy of a Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with ASPH+Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck. See PDF here.

Refractory Head and Neck Cancer Enrollment Update

PresentationBy Sensei TeamDecember 12, 2020

Early Safety and Efficacy of a Phase 1/2 Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced SquamousCell Carcinoma of the Head and Neck. See PDF here.

SITC TIP

PresentationBy Sensei TeamDecember 12, 2020

Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced Squamous Cell Carcinoma of the Head & Neck. See PDF here.

Blog Topics
  • Featured(1)
  • Presentation(3)
  • Press Release(24)
  • Publication(16)
  • Recent(1)
Recent Posts
  • Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
  • SITC Safety and Efficacy
  • Refractory Head and Neck Cancer Enrollment Update
  • SITC TIP
  • Iwagami Y et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 2017, PMID: 28971150
About

We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Contact
Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850
Phone No
phone

+1.240.243.8000

Boston R&D Location
Smart Labs, Seaport District
6 Tide Street
Boston, MA 02210
Email
phone

info@senseibio.com

© 2021 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top